Recent Updates — SNWV

Sanuwave Health entered into Amendment No. 1 to its Credit Agreement, securing a waiver from lenders for any defaults related to the fixed charge coverage ratio for the twelve-month period ending September 30, 2026. The amendment imposes stricter covenants, requiring written consent for permitted acquisitions and equity repurchases, while lowering limits on other secured indebtedness and subsidiary investments from $500,000 to $250,000 each. The company also agreed to pay a $5,000 amendment fee. Sanuwave Health develops medical devices for the treatment of chronic pain.

Sanuwave Health, Inc. received a notice from Nasdaq on September 23, 2026, indicating its Market Value of Listed Securities fell below the $50 million minimum requirement for continued listing on The Nasdaq Global Market over the last 30 consecutive business days. The company has an 180-day compliance period ending March 22, 2027, to restore compliance by maintaining a market value of at least $50 million for ten consecutive business days. Failure to meet this threshold may result in delisting, though the company may apply to transfer to The Nasdaq Capital Market if applicable requirements are satisfied. Sanuwave Health operates in the medical technology industry, developing and commercializing neuromodulation therapies.

Sanuwave Health, Inc. reported second quarter 2026 financial results with revenue of $9.7 million, a 3% decline from the prior year period. Gross margin decreased to 76.2% from 78.1%, and GAAP operating income turned to a loss of $(0.3) million compared to $1.4 million previously. The company withdrew its fiscal year 2026 financial guidance due to uncertainty surrounding CMS reimbursement changes for wound care treatments. System sales declined to 82 units from 116 in the prior year, while applicator revenue grew 13% to $7.3 million. Sanuwave operates in the medical device industry, specializing in FDA-cleared regenerative medicine and wound care products.

Sanuwave Health, Inc. issued a press release on July 13, 2026, announcing preliminary financial results for the quarter ended June 30, 2026. The company is in the healthcare technology industry, providing medical devices and therapeutic solutions.

Sanuwave Health, Inc. issued a press release on June 16, 2026, providing updated financial guidance for the fiscal quarter ending June 30, 2026. The specific details of the updated guidance are contained in the attached Exhibit 99.1. Sanuwave Health, Inc. is a medical technology company.